A detailed history of Fortitude Family Office, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Fortitude Family Office, LLC holds 18 shares of HALO stock, worth $950. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18
Previous 18 -0.0%
Holding current value
$950
Previous $1.03 Million 16.41%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$51.3 - $64.42 $923 - $1,159
18 New
18 $1.03 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.35B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Fortitude Family Office, LLC Portfolio

Follow Fortitude Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortitude Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fortitude Family Office, LLC with notifications on news.